Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer?

Since 2010, several treatment options have been available for men with metastatic castration-resistant prostate cancer (mCRPC), including immunotherapeutic agents, although the clinical benefit of these agents remains inconclusive in unselected mCRPC patients. In recent years, however, immunotherapy...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Int J Mol Sci
मुख्य लेखकों: Ruiz de Porras, Vicenç, Pardo, Juan Carlos, Notario, Lucia, Etxaniz, Olatz, Font, Albert
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: MDPI 2021
विषय:
Review
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC8124759/
https://ncbi.nlm.nih.gov/pubmed/33946818
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms22094712
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन